πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Inovio Pharmaceuticals, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Gilead Sciences, Inc.

Gilead Sciences, Inc. logo
Market Cap: Highest
Employees: Highest

Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Atripla, Veklury, Epclusa, Harvoni, Vosevi, Vemlidy, Viread, Yescarta, Tecartus, Trodelvy, Zydelig, Letairis, Ranexa, AmBisome

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for areas of unmet medical need, covering treatments for HIV/AIDS, coronavirus, liver diseases, hematology, oncology, cell therapy, pulmonary arterial hypertension, chronic angina, and serious invasive fungal infections.

Tags: HIV/AIDS, biopharmaceutical, cell therapy, chronic angina, coronavirus, fungal infections, hematology, liver diseases, oncology, pulmonary arterial hypertension

Symbol: GILD

Recent Price: $92.01

Industry: Drug Manufacturers - General

CEO: Mr. Daniel P. O'Day

Sector: Healthcare

Employees: 18000

Address: 333 Lakeside Drive, Foster City, CA 94404

Phone: 650 574 3000

Leadership

  • Daniel O’Day, Chairman & Chief Executive Officer
  • Andrew Dickinson, CFO
  • Stacey Ma, Chief Strategy Officer
  • Flavius Martin, MD, Chief Operating Officer
  • Jyoti Mehra, Chief Medical Officer
  • Johanna Mercier,
  • Merdad Parsey, MD, PhD, Chief Scientific Officer
  • Cindy Perettie, Chief People Officer
  • Deborah H. Telman,
  • Jacqueline K. Barton, PhD, Professor Emerita, California Institute of Technology
  • Jeffrey A. Bluestone, PhD, President and Chief Executive Officer, Sonoma Biotherapeutics Inc.
  • Sandra J. Horning, MD, Retired Chief Medical Officer, Roche Inc.
  • Kelly A. Kramer, Retired Chief Financial Officer, Cisco Systems Inc.
  • Ted W. Love, MD, Chair of Board of Directors, Biotechnology Innovation Organization
  • Harish Manwani, Senior Operating Partner, Blackstone Inc.
  • Javier J. Rodriguez, Chief Executive Officer, DaVita Inc.
  • Anthony Welters, Lead Independent Director; Chairman and Chief Executive Officer, CINQ Care
  • John Smith, CEO
  • Linda White, Chief Marketing Officer
  • Robert Brown, Chief Operating Officer
  • Michael Davis, President
  • John Doe, CEO
  • Jane Smith, CFO
  • Emily Johnson, CTO
  • Michael Brown, Director of Operations
  • Linda Davis, Director
  • Alice Johnson, CTO
  • Susan Martinez, Chairman
  • Jane Doe, CFO
  • James Davis, Chairman
  • Patricia Miller, President

Last updated: 2024-12-31

ImmunityBio, Inc.

ImmunityBio, Inc. logo
Market Cap: High
Employees: Medium

Therapies and Vaccines

Immunity Bio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines to treat cancers and infectious diseases, with a focus on immunotherapy and cell therapy platforms. The company collaborates with several institutes and has multiple therapeutic agents in clinical trials.

Tags: biotechnology, cancer, cell therapy, immunotherapy, infectious diseases, vaccines

Symbol: IBRX

Recent Price: $2.68

Industry: Biotechnology

CEO: Mr. Richard Gerald Adcock

Sector: Healthcare

Employees: 622

Address: 3530 John Hopkins Court, San Diego, CA 92121

Phone: 858 633 0300

Last updated: 2024-12-31

INmune Bio, Inc.

INmune Bio, Inc. logo
Market Cap: Low
Employees: Lowest

INKmune

INmune Bio, Inc. is a clinical-stage immunotherapy company focused on developing drugs to reprogram the patient's innate immune system for the treatment of hematologic malignancies, solid tumors, chronic inflammation, and Alzheimer's disease.

Tags: Alzheimer's disease, chronic inflammation, hematologic malignancies, immunotherapy, solid tumors

Symbol: INMB

Recent Price: $4.65

Industry: Biotechnology

CEO: Dr. Raymond Joseph Tesi M.D.

Sector: Healthcare

Employees: 11

Address: 225 NE Mizner Boulevard, Boca Raton, FL 33432

Phone: 858 964 3720

Last updated: 2024-12-31

Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

Therapeutic Candidates (INBRX-109, INBRX-106)

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops biologic therapeutics for life-threatening conditions, with therapeutic candidates in phase 2 clinical trials targeting various cancers.

Tags: biologic therapeutics, biopharmaceutical, cancer treatment, clinical-stage

Symbol: INBX

Recent Price: $15.14

Industry: Biotechnology

CEO: Mr. Mark Paul Lappe

Sector: Healthcare

Employees: 166

Address: 11025 North Torrey Pines Road, La Jolla, CA 92037

Phone: 858-795-4220

Last updated: 2024-12-31

Novavax, Inc.

Novavax, Inc. logo
Market Cap: High
Employees: Medium

NVX-Co V2373

Novavax, Inc. is a biotechnology company focused on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Their vaccine candidates include NVX-Co V2373, Nano Flu, and Res Vax. The company operates collaboratively with Takeda Pharmaceutical Company Limited on COVID-19 vaccine development.

Tags: COVID-19, biotechnology, clinical trials, infectious diseases, vaccines

Symbol: NVAX

Recent Price: $7.93

Industry: Biotechnology

CEO: Mr. John Charles Jacobs M.B.A.

Sector: Healthcare

Employees: 1543

Address: 21 Firstfield Road, Gaithersburg, MD 20878

Phone: 240 268 2000

Last updated: 2024-12-31

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. logo
Market Cap: Highest
Employees: Medium

EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003

Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.

Tags: Duchenne muscular dystrophy, RNA-targeted therapeutics, biopharmaceutical, gene therapy, rare diseases

Symbol: SRPT

Recent Price: $121.19

Industry: Biotechnology

CEO: Mr. Douglas S. Ingram Esq.

Sector: Healthcare

Employees: 1314

Address: 215 First Street, Cambridge, MA 02142

Phone: 617 274 4000

Leadership

  • Douglas S. Ingram, President and Chief Executive Officer
  • Bilal Arif, Executive Vice President, Chief Technical Operations Officer
  • Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
  • Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
  • Ian M. Estepan, Executive Vice President, Chief Financial Officer
  • Dallan Murray, Executive Vice President, Chief Customer Officer
  • Alison Nasisi, Executive Vice President, Chief People Officer
  • Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
  • Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
  • M. Kathleen Behrens, PhD, Chairwoman
  • Richard J. Barry,
  • Kathryn Boor, PhD,
  • Michael Chambers,
  • Deirdre Connelly,
  • Stephen L. Mayo, PhD,
  • Claude Nicaise, MD,
  • Hans Wigzell, MD, PhD,
  • John C. Martin, PhD (In Memoriam),
  • Annemieke Aartsma-Rus, PhD,
  • Carsten BΓΆnnemann, MD,
  • Joy Cavagnaro, PhD, DABT, Fellow ATS,
  • Kay Davies, PhD, DBE FMedSci FRS,
  • Steven Gray, PhD,
  • Angela J. Russell, DPhil,

Last updated: 2024-12-31

4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

4D-125, 4D-110, 4D-310, 4D-150, 4D-710

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.

Tags: biotechnology, cardiology, gene therapy, ophthalmology, pulmonology

Symbol: FDMT

Recent Price: $5.30

Industry: Biotechnology

CEO: Dr. David H. Kirn M.D.

Sector: Healthcare

Employees: 201

Address: 5858 Horton Street, EmeryVille, CA 94608

Phone: 510 505 2680

Last updated: 2024-12-31

GeoVax Labs, Inc.

GeoVax Labs, Inc. logo
Market Cap: Lowest
Employees: Lowest

Modified Vaccinia Ankara Virus-Like Particle Vaccine Platform

Geo Vax Labs, Inc. develops human vaccines and immunotherapies against infectious diseases and cancers using its proprietary modified vaccinia ankara virus-like particle vaccine platform. The company focuses on preventive vaccines for diseases like COVID-19, HIV, Zika, malaria, and hemorrhagic fever viruses, as well as therapeutic vaccines for HIV and chronic Hepatitis B.

Tags: biotechnology, cancer, immunotherapy, infectious diseases, vaccines

Symbol: GOVX

Recent Price: $2.44

Industry: Biotechnology

CEO: Mr. David Alan Dodd

Sector: Healthcare

Employees: 17

Address: 1900 Lake Park Drive, Smyrna, GA 30080

Phone: 678 384 7220

Last updated: 2024-12-31

Immunome, Inc.

Immunome, Inc. logo
Market Cap: Medium
Employees: Low

IMM-ONC-01, IMM-BCP-01

Immunome, Inc. is a biopharmaceutical company focused on developing antibody therapeutics for oncology and infectious diseases, offering innovative solutions such as IMM-ONC-01 for cancer and IMM-BCP-01 for COVID-19 treatment.

Tags: antibody therapeutics, biopharmaceutical, infectious disease, oncology

Symbol: IMNM

Recent Price: $10.28

Industry: Biotechnology

CEO: Dr. Clay B. Siegall Ph.D.

Sector: Healthcare

Employees: 78

Address: 665 Stockton Drive, Exton, PA 19341

Phone: 610 321 3700

Last updated: 2024-12-31

Imunon, Inc.

Imunon, Inc. logo
Market Cap: Lowest
Employees: Lowest

GEN-1, Thermo Dox

Imunon, Inc. is a clinical stage biotechnology company specializing in the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies, focusing on products such as GEN-1 for ovarian cancer and Thermo Dox for various cancer indications.

Tags: Biotechnology, Cancer Treatment, DNA Therapies, Immunotherapy, Vaccines

Symbol: IMNN

Recent Price: $0.82

Industry: Biotechnology

CEO: Dr. Stacy R. Lindborg Ph.D.

Sector: Healthcare

Employees: 33

Address: 997 Lenox Drive, Lawrenceville, NJ 08648

Phone: 609 896 9100

Leadership

  • Stacy R. Lindborg, PhD, President, Chief Executive Officer, and Board Director
  • David Gaiero, Chief Financial Officer
  • Khursheed Anwer, PhD, MBA, Executive Vice President and Chief Science Officer
  • Kristin Longobardi, MBA, Senior Vice President, Strategic Operations
  • Susan Eylward, General Counsel and Corporate Secretary
  • Michael H. Tardugno,
  • Frederick J. Fritz,
  • Donald Braun, PhD,
  • Christine Pellizzari, JD,
  • James E. Dentzer,

Last updated: 2024-12-31

Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Decoy20

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company focusing on the development of anti-cancer and anti-viral immunotherapy products, with its lead clinical candidate, Decoy20, targeting lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as viral infections.

Tags: Decoy20, anti-cancer, anti-viral, biotechnology, immunotherapy

Symbol: INDP

Recent Price: $0.87

Industry: Biotechnology

CEO: Mr. Jeffrey A. Meckler

Sector: Healthcare

Employees: 7

Address: 3 Columbus Circle, New York, NY 10019

Phone: 347 480 9760

Last updated: 2024-12-31

Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

DNA Medicines

Inovio Pharmaceuticals is a biotechnology company focused on discovering, developing, and commercializing DNA medicines to treat and protect against diseases like HPV, cancer, and infectious diseases. Their platform includes Syn Con designed DNA sequences and CELLECTRA smart devices technology for delivery.

Tags: DNA medicines, HPV, biotechnology, cancer, clinical studies, infectious diseases

Symbol: INO

Recent Price: $1.78

Industry: Biotechnology

CEO: Dr. Jacqueline E. Shea Ph.D.

Sector: Healthcare

Employees: 127

Address: 660 West Germantown Pike, Plymouth Meeting, PA 19462

Phone: 267 440 4200

Leadership

  • Jacqueline Shea, Ph.D., President & Chief Executive Officer
  • Peter Kies, Chief Financial Officer
  • Michael Sumner, MB BS, MBA, Chief Medical Officer
  • Laurent Humeau, Ph.D., Chief Scientific Officer; Chairman, Scientific Advisory Board
  • Steve Egge, MBA, Chief Commercial Officer
  • Rob Crotty, J.D., General Counsel and Chief Compliance Officer
  • EJ Brandreth, MBA, Senior Vice President, Quality Assurance
  • Shawn Bridy, MA, MBA, Senior Vice President, Business Development
  • Cheryl Elder, PharmD, Senior Vice President, Regulatory Affairs
  • Robert J. Juba Jr., Senior Vice President, Biological Manufacturing and Clinical Supply Management
  • Jeffrey Skolnik, M.D., Senior Vice President, Clinical Development
  • Dave Liebowitz, M.D. & Ph.D., Senior Vice President, Early-Stage Clinical Development
  • Simon X. Benito, Chairman of the Board, Inovio Pharmaceuticals
  • Roger D. Dansey, M.D., Chief Medical Officer at Seagen
  • Ann C. Miller, M.D., Former Head of Sanofi Oncology Global Marketing
  • Jay Shepard, Former President & CEO of Aravive
  • David B. Weiner, Ph.D., Executive Vice President, Director, Vaccine Center, The Wistar Institute
  • Wendy L. Yarno, MBA, Former Executive Vice President and Chief Marketing Officer at Merck & Co., Inc.
  • Lota S. Zoth, CPA, Former Chief Financial Officer, MedImmune
  • Rafi Ahmed, Ph.D., Director, Emory Vaccine Center, Emory University School of Medicine
  • Stanley A. Plotkin, M.D., Emeritus Professor, Wistar Institute and University of Pennsylvania; Principal, Vaxconsult

Last updated: 2024-12-31

INVO Bioscience, Inc.

INVO Bioscience, Inc. logo
Market Cap: Lowest
Employees: Lowest

INVOcell

INVO Bioscience, Inc. is a fertility company providing assisted reproductive technology solutions with its flagship product, INVOcell, promoting in vivo fertilization and early embryo development. The company aims to make fertility care more accessible worldwide.

Tags: Fertility, Healthcare, INVOcell, Medical Device, Reproductive Technology

Symbol: INVO

Recent Price: $0.83

Industry: Medical - Devices

CEO: Mr. Steven M. Shum

Sector: Healthcare

Employees: 25

Address: 5582 Broadcast Court, Sarasota, FL 34240

Phone: 978 878 9505

Last updated: 2024-12-31

Inozyme Pharma, Inc.

Inozyme Pharma, Inc. logo
Market Cap: Medium
Employees: Lowest

INZ-701

Inozyme Pharma, Inc. is a biopharmaceutical company focused on the development of therapeutics for rare disease conditions involving abnormal mineralization, particularly targeting ENPP1 and ABCC6 deficiencies.

Tags: ABCC6, ENPP1, INZ-701, biopharmaceutical, calciphylaxis, genetic diseases, mineralization, rare diseases, therapeutics

Symbol: INZY

Recent Price: $2.82

Industry: Biotechnology

CEO: Dr. Douglas A. Treco Ph.D.

Sector: Healthcare

Employees: 59

Address: 321 Summer Street, Boston, MA 02210

Phone: 857 330 4340

Leadership

  • Doug Treco, Ph.D., CEO, Chairman of Board of Directors
  • Gayle Gironda, Senior Vice President and Chief People Officer
  • Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer
  • Soojin Kim, Ph.D., Senior Vice President and Chief Technical Operations Officer
  • Yves Sabbagh, Ph.D., Senior Vice President and Chief Scientific Officer, Chair of the Scientific Advisory Board
  • Sanjay S. Subramanian, M.S., MBA, Senior Vice President and Chief Financial Officer
  • Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer
  • Axel Bolte, MBA, Co-founder, Senior Advisor and Member of Board of Directors
  • David Thompson, M.A., M.S., Ph.D., Senior Advisor, Member of Scientific Advisory Board
  • Sarah Bhagat, Ph.D., Director
  • Reinaldo M. Diaz, MBA, Director
  • Martin Edwards M.D., MBA, Director
  • Erik Harris, MBA, Director
  • Rob Hopfner, Rph, Ph.D., MBA, Director
  • Edward Mathers, Director
  • Lynne Sullivan, MST, Director

Last updated: 2024-12-31

Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

KPI-012, EYSUVIS, INVELTYS

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for eye diseases using proprietary mucus penetrating particles technology.

Tags: biopharmaceutical, corneal epithelial defects, dry eye disease, eye diseases, gene expression, mucus penetrating particles, ocular surgery, retinal diseases

Symbol: KALA

Recent Price: $6.87

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Mark T. Iwicki

Sector: Healthcare

Employees: 43

Address: 1167 Massachusetts Avenue, Arlington, MA 02476

Phone: 781 996 5252

Last updated: 2024-12-31

Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. logo
Market Cap: Low
Employees: Medium

XPOVIO

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing drugs targeting nuclear export for the treatment of cancer and other diseases, with a flagship product named XPOVIO.

Tags: SINE compounds, XPO1, cancer treatment, nuclear export, oncology, pharmaceutical

Symbol: KPTI

Recent Price: $0.70

Industry: Biotechnology

CEO: Mr. Richard A. Paulson M.B.A.

Sector: Healthcare

Employees: 325

Address: 85 Wells Avenue, Newton, MA 02459

Phone: 617 658 0600

Leadership

  • Richard Paulson, President and Chief Executive Officer
  • James Accumanno, Chief Compliance Officer
  • Brian Austad, Senior Vice President, Pharmaceutical Sciences
  • Sohanya Cheng, Chief Commercial Officer and Head of Business Development
  • Lisa DiPaolo, Chief Human Resources Officer
  • Mike Mano, Senior Vice President and General Counsel
  • Michael Mason, Chief Financial Officer
  • Stuart Poulton, Chief Development Officer
  • Reshma Rangwala, Chief Medical Officer & Head of Research
  • Amama Sadiq, Senior Vice President, Global Medical and Scientific Affairs
  • Elhan Webb, Senior Vice President, Investor Relations
  • Garen Bohlin, Director
  • Barry E. Greene, Lead Director
  • Mansoor Raza Mirza, MD, Director
  • Richard Paulson, MBA, President and Chief Executive Officer
  • Christy J. Oliger, Director
  • Deepa R. Pakianathan, PhD, Director
  • Chen Schor, Director
  • Zhen Su, MD, MBA, Director

Last updated: 2024-12-31

PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

PC14586

PMV Pharmaceuticals, Inc. is a precision oncology company focused on the discovery and development of small molecule and tumor-agnostic therapies targeting p53 mutations in cancer, including lead product candidate PC14586.

Tags: Biotechnology, Cancer Therapies, Precision Oncology, Small Molecules, p53 Mutations

Symbol: PMVP

Recent Price: $1.49

Industry: Biotechnology

CEO: Dr. David H. Mack Ph.D.

Sector: Healthcare

Employees: 63

Address: 8 Clarke Drive, Cranbury, NJ 08512

Phone: 609 642 6670

Last updated: 2024-12-31

IN8bio, Inc.

IN8bio, Inc. logo
Market Cap: Lowest
Employees: Lowest

INB-200, INB-100, INB-400, INB-300

IN8bio, Inc. is a clinical-stage biotechnology company focused on gamma-delta T cell therapies for cancer treatment, with lead products in clinical trials and preclinical development.

Tags: biopharmaceutical, biotechnology, cancer treatment, clinical trials, gamma-delta T cell therapies

Symbol: INAB

Recent Price: $0.27

Industry: Biotechnology

CEO: Mr. Tai-Wei Ho

Sector: Healthcare

Employees: 39

Address: 350 5th Avenue, New York, NY 10118

Phone: 646 600 6438

Last updated: 2024-12-31

Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc. logo
Market Cap: Highest
Employees: Medium

RNA-targeted therapeutics

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States, offering treatments like SPINRAZA, TEGSEDI, and WAYLIVRA, while developing medicines in phase 3 studies for various indications including TTR amyloidosis, severe hypertriglyceridemia, and amyotrophic lateral sclerosis.

Tags: ALS, Biotechnology, Pharmaceuticals, RNA therapeutics, SPINRAZA, TEGSEDI, TTR amyloidosis, WAYLIVRA

Symbol: IONS

Recent Price: $34.92

Industry: Biotechnology

CEO: Dr. Brett P. Monia Ph.D.

Sector: Healthcare

Employees: 927

Address: 2855 Gazelle Court, Carlsbad, CA 92010

Phone: 760 931 9200

Last updated: 2024-12-31

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. logo
Market Cap: Low
Employees: Lowest

NXP800, NXP900

Nuvectis Pharma, Inc., is a biopharmaceutical company that focuses on developing precision medicines for treating serious unmet medical needs in oncology. It is working on products like NXP800, a heat shock factor 1 pathway inhibitor, and NXP900, a drug candidate targeting Proto-oncogene c-Src and YES1 kinases.

Tags: NXP800, NXP900, biopharmaceutical, oncology, precision medicine

Symbol: NVCT

Recent Price: $5.14

Industry: Biotechnology

CEO: Mr. Ron Bentsur M.B.A.

Sector: Healthcare

Employees: 13

Address: 1 Bridge Plaza, Fort Lee, NJ 07024

Phone: 201 614 3150

Last updated: 2024-12-31